RU97112089A - SOLID PHARMACEUTICAL COMPOSITION WITH REGULATED MEDICINAL RELEASE - Google Patents

SOLID PHARMACEUTICAL COMPOSITION WITH REGULATED MEDICINAL RELEASE

Info

Publication number
RU97112089A
RU97112089A RU97112089/14A RU97112089A RU97112089A RU 97112089 A RU97112089 A RU 97112089A RU 97112089/14 A RU97112089/14 A RU 97112089/14A RU 97112089 A RU97112089 A RU 97112089A RU 97112089 A RU97112089 A RU 97112089A
Authority
RU
Russia
Prior art keywords
composition according
acid
alginate
sodium alginate
drug
Prior art date
Application number
RU97112089/14A
Other languages
Russian (ru)
Other versions
RU2142793C1 (en
Inventor
Невил У. Борд
Элан Ф. Кармоди
Брайен К. Уизерз
Лайэм К. Фили
Original Assignee
Абботт Лаборэтриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/574,877 external-priority patent/US5705190A/en
Application filed by Абботт Лаборэтриз filed Critical Абботт Лаборэтриз
Publication of RU97112089A publication Critical patent/RU97112089A/en
Application granted granted Critical
Publication of RU2142793C1 publication Critical patent/RU2142793C1/en

Links

Claims (19)

1. Твердая фармацевтическая композиция с регулируемым высвобождением лекарственного средства для орального употребления, включающая терапевтически эффективное количество по крайней мере одного основного лекарственного средства, имеющего растворимость в воде менее, чем 1 ч. на 30 ч. воды, водорастворимую альгинатную соль, комплексную соль альгиновой кислоты и эффективное количество органической карбоксильной кислоты для облегчения растворения основного лекарства.1. Solid pharmaceutical composition with controlled release of the medicinal product for oral use, comprising a therapeutically effective amount of at least one basic drug having a solubility in water of less than 1 part per 30 parts of water, a water-soluble alginate salt, a complex salt of alginic acid and an effective amount of an organic carboxylic acid to facilitate dissolution of the main drug. 2. Композиция по п. 1, отличающаяся тем, что она имеет форму таблетки. 2. The composition according to p. 1, characterized in that it has the form of a tablet. 3. Композиция по п. 1, отличающаяся тем, что она имеет форму препарата для схемы приема лекарственного средства один раз в день. 3. The composition according to p. 1, characterized in that it has the form of a drug for the regimen of taking the drug once a day. 4. Композиция по п. 1, отличающаяся тем, что она содержит в качестве основного лекарственного средства макролид. 4. The composition according to p. 1, characterized in that it contains macrolide as the main drug. 5. Композиция по п. 4, отличающаяся тем, что макролидом является кларитромицин. 5. The composition according to p. 4, characterized in that the macrolide is clarithromycin. 6. Композиция по п. 1, отличающаяся тем, что она содержит в качестве водорастворимой альгинатной соли альгинат натрия. 6. The composition according to p. 1, characterized in that it contains sodium alginate as a water-soluble alginate salt. 7. Композиция по п. 1, отличающаяся тем, что она содержит в качестве комплексной соли альгиновой кислоты альгинат натрия-кальция. 7. The composition according to claim 1, characterized in that it contains sodium-calcium alginate as a complex salt of alginic acid. 8. Композиция по п. 1, отличающаяся тем, что она содержит в качестве органической карбоновой кислоты соединение, выбранное из группы, включающей винную кислоту, яблочную кислоту, янтарную кислоту, глутаровую кислоту, глютаминовую кислоту, малеиновую кислоту, миндальную кислоту и лимонную кислоту. 8. The composition according to p. 1, characterized in that it contains as an organic carboxylic acid a compound selected from the group consisting of tartaric acid, malic acid, succinic acid, glutaric acid, glutamic acid, maleic acid, mandelic acid and citric acid. 9. Композиция по п. 8, отличающаяся тем, что в качестве органической карбоновой кислоты она содержит лимонную кислоту. 9. The composition according to claim 8, characterized in that it contains citric acid as an organic carboxylic acid. 10. Композиция по п. 1, отличающаяся тем, что она содержит водорастворимую альгинатную соль и комплексную соль альгиновой кислоты при их массовом соотношении соответственно от 16: 1 до 1: 1. 10. The composition according to p. 1, characterized in that it contains a water-soluble alginate salt and a complex salt of alginic acid in their mass ratio, respectively, from 16: 1 to 1: 1. 11. Композиция по п. 10, отличающаяся тем, что она содержит альгинат натрия и альгинат натрия-кальция, при их массовом соотношении соответственно от 16: 1 до 1: 1. 11. The composition according to p. 10, characterized in that it contains sodium alginate and sodium alginate-calcium, with their mass ratio, respectively, from 16: 1 to 1: 1. 12. Композиция по п. 11, отличающаяся тем, что она содержит альгинат натрия и альгинат натрия-кальция при их массовом соотношении соответственно от 8: 1 до 2: 1. 12. The composition according to p. 11, characterized in that it contains sodium alginate and sodium calcium alginate in a weight ratio of 8: 1 to 2: 1, respectively. 13. Композиция по п. 1, отличающаяся тем, что она содержит органическую карбоновую кислоту и основное лекарственное средство при их молярном соотношении соответственно от 0,2: 1 до 5: 1. 13. The composition according to p. 1, characterized in that it contains an organic carboxylic acid and the main drug in their molar ratio, respectively, from 0.2: 1 to 5: 1. 14. Композиция по п. 1, отличающаяся тем, что она содержит органическую карбоновую кислоту и основное лекарственное средство при их молярном соотношении 1: 1. 14. The composition according to p. 1, characterized in that it contains organic carboxylic acid and the main drug in their molar ratio of 1: 1. 15. Композиция по п. 1, отличающаяся тем, что она содержит основное лекарственное средство, выбранное из группы, включающей сульфометоксазол, метронидазол, циметидин, индапаамид, атенолол диазепам. 15. The composition according to p. 1, characterized in that it contains the main drug selected from the group comprising sulfomethoxazole, metronidazole, cimetidine, indapamide, atenolol diazepam. 16. Композиция по п. 4, отличающаяся тем, что она содержит макролид, выбранный из группы, включающей эритромицин, диритромицин, азитромицин, рокситромицин и АВТ-229. 16. The composition according to p. 4, characterized in that it contains a macrolide selected from the group consisting of erythromycin, dirithromycin, azithromycin, roxithromycin and ABT-229. 17. Композиция для орального употребления лекарственного средства по схеме приема один раз в день по п. 1, отличающаяся тем, что она включает в себя 500 мг кларитромицина, 75 - 400 мг альгината натрия 10 - 400 мг альгината натрия-кальция и 128 мг лимонной кислоты. 17. The composition for oral administration of the drug according to the once-daily regimen according to claim 1, characterized in that it includes 500 mg of clarithromycin, 75 to 400 mg of sodium alginate, 10 to 400 mg of sodium calcium alginate and 128 mg of lemon acids. 18. Композиция по п. 17, отличающаяся тем, что она включает 80 - 200 мг альгината натрия и 10 - 40 мг альгината натрия-кальция. 18. The composition according to p. 17, characterized in that it comprises 80 to 200 mg of sodium alginate and 10 to 40 mg of sodium alginate calcium. 19. Композиция по п. 18, отличающаяся тем, что она включает 120 мг альгината натрия и 15 мг альгината натрия-кальция. 19. The composition according to p. 18, characterized in that it comprises 120 mg of sodium alginate and 15 mg of sodium alginate calcium.
RU97112089A 1995-12-19 1996-11-25 Controlled-release drug solid pharmaceutical composition RU2142793C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/574,877 US5705190A (en) 1995-12-19 1995-12-19 Controlled release formulation for poorly soluble basic drugs
US08/574,877 1995-12-19
PCT/US1996/018960 WO1997022335A1 (en) 1995-12-19 1996-11-25 A controlled release formulation for poorly soluble basic drugs

Publications (2)

Publication Number Publication Date
RU97112089A true RU97112089A (en) 1999-06-10
RU2142793C1 RU2142793C1 (en) 1999-12-20

Family

ID=24298013

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97112089A RU2142793C1 (en) 1995-12-19 1996-11-25 Controlled-release drug solid pharmaceutical composition

Country Status (27)

Country Link
US (1) US5705190A (en)
EP (1) EP0799028B1 (en)
JP (1) JP3292732B2 (en)
KR (1) KR100632187B1 (en)
CN (1) CN1131027C (en)
AR (1) AR004391A1 (en)
AT (2) ATE170744T1 (en)
AU (1) AU701268B2 (en)
CA (1) CA2209714C (en)
CZ (1) CZ289158B6 (en)
DE (2) DE29624506U1 (en)
DK (1) DK0799028T3 (en)
ES (1) ES2122810T3 (en)
HK (1) HK1016873A1 (en)
HU (1) HUP9800516A3 (en)
IL (1) IL121275A (en)
IT (1) ITMI20050383U1 (en)
NZ (1) NZ323332A (en)
PL (1) PL186696B1 (en)
PT (1) PT103379B (en)
RO (1) RO117501B1 (en)
RU (1) RU2142793C1 (en)
TR (1) TR199800777T2 (en)
TW (1) TW429154B (en)
UA (1) UA40663C2 (en)
WO (1) WO1997022335A1 (en)
ZA (1) ZA9610110B (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6068859A (en) 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
SI20108B (en) * 1997-06-11 2001-12-31 Abbott Lab A controlled release formulation for poorly soluble basic drugs
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
SI1064942T1 (en) * 1998-03-26 2004-12-31 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparation of a macrolide
EE05054B1 (en) * 1998-08-21 2008-08-15 Novartis Ag Oral pharmaceutical composition of a 5-HT4 agonist or antagonist and its use in medicine
IT1313610B1 (en) 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti PROCESS FOR THE PREPARATION OF AQUEOUS FORMULATIONS FOR OPHTHALMIC USE
TR200000054A2 (en) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Sustained-release tablet formulations containing clarithromycin.
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
EP1313486A1 (en) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
MXPA02009587A (en) * 2000-03-28 2003-05-14 Biochemie Gmbh Granulated particles with masked taste.
DE10031043A1 (en) * 2000-06-26 2002-02-14 Bayer Ag Retarded preparations of quinolone antibiotics and process for their preparation
IN192748B (en) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
WO2003017981A1 (en) 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
EA200400343A1 (en) * 2001-08-29 2004-08-26 Рэнбакси Лабораториз Лимитед COMPOSITION WITH CONTROLLED SURVIVAL OF CLARITROMYCIN OR TINIDAZOL
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
US20030091627A1 (en) * 2001-10-31 2003-05-15 Vinay Sharma Rate-controlled delivery of macrolides
CA2465405A1 (en) * 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
PT1485078E (en) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran for the treatment of irritable bowel syndrome
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
SI21300A (en) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical compositions with alginates
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
CA2513893A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
AU2004238253B2 (en) * 2003-05-06 2011-01-27 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
CA2529746C (en) * 2003-06-16 2010-08-03 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
JP2007502296A (en) * 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2540104A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles comprising inclusion complexes
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2547773A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
BRPI0417348A (en) * 2003-12-04 2007-03-13 Pfizer Prod Inc spray gelatinization process using an extruder for preparing multiparticulate crystalline drug compositions preferably containing a poloxamer and a glyceride
AU2004294817B2 (en) * 2003-12-04 2007-01-25 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
EP1694304A2 (en) * 2003-12-04 2006-08-30 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
EP1691786A1 (en) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
US20050142187A1 (en) * 2003-12-24 2005-06-30 Treacy Donald J.Jr. Enhanced absorption of modified release dosage forms
CN100435847C (en) * 2004-05-13 2008-11-26 宝龄富锦生技股份有限公司 Continuing release recipe of containing infusible basic remedy
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
EP1765336A4 (en) 2004-06-25 2010-03-10 Univ Johns Hopkins Angiogenesis inhibitors
EP1771158A4 (en) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Tablet for pulsed delivery
CN1322866C (en) * 2004-10-12 2007-06-27 广州贝氏药业有限公司 Multi-unit slow-release preparation
DE102005042875A1 (en) * 2004-12-23 2006-09-21 Grünenthal GmbH Fast-release dosage forms for antibiotics
EP1904041A2 (en) * 2005-07-07 2008-04-02 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
US20070128272A1 (en) * 2005-12-07 2007-06-07 Zerbe Horst G Multi-vitamin and mineral supplement
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
KR20140088230A (en) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 Drug delivery systems comprising weakly basic drugs and organic acids
EP1976491B1 (en) * 2006-01-27 2014-12-17 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (en) * 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
DK2234607T3 (en) * 2007-12-28 2011-11-21 Acraf Slow release formulation based on a compound of glycogen and alginate
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CN102239149B (en) 2008-10-06 2015-05-13 约翰·霍普金斯大学 Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
US8900680B2 (en) * 2009-05-29 2014-12-02 Tetra Laval Holdings & Finanace S.A. Packaging material comprising magnetisable portions
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2451444A1 (en) * 2009-07-07 2012-05-16 Sunovion Pharmaceuticals Inc. Formulations of 6- (5-chloro-2-pyridyl) - 5- [ (4-methyl-1-piperazinyl) carbonyloxy]- 7-0x0-6, 7- dihydro- 5h- phyrrolo [3, 4-b]pyrazine
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
US20120219625A1 (en) * 2009-09-02 2012-08-30 Bernard Charles Sherman Clarithromycin extended-release tablet
CN102106807B (en) * 2009-12-29 2013-03-27 上海中西制药有限公司 Method for preparing solid preparation and solid preparation
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
CN103442698B (en) 2010-12-16 2016-10-05 细胞基因公司 Controlled release oral dosage form of insoluble drug and application thereof
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
DE102013202703B4 (en) 2013-02-20 2020-03-12 Siemens Healthcare Gmbh Device and method for collision detection in a medical device
CN105377292A (en) 2013-04-07 2016-03-02 博德研究所 Compositions and methods for personalized neoplasia vaccines
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (en) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 Combination therapy with neoantigen vaccine
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
JP6913032B2 (en) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド Common neoantigen
US10383825B2 (en) * 2015-08-13 2019-08-20 Temple University—Of the Commonwealth System of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
AU2018265624A1 (en) * 2017-05-11 2019-12-05 Steadymed, Ltd. Enhanced solubility drug-containing formulations
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN111184699A (en) * 2020-04-09 2020-05-22 河北大学 Nifedipine controlled release capsule and preparation method thereof
KR20230029673A (en) 2020-05-26 2023-03-03 디오니스 테라퓨틱스, 아이엔씨. Nucleic acid artificial mini-proteome library
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296140A (en) * 1977-03-08 1981-10-20 Tri/Valley Growers Molded gelled pimiento body
GB1566609A (en) * 1977-03-10 1980-05-08 Reckitt & Colmann Prod Ltd Pharmaceutical compositions containing cholestyramine and alginic acid
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
JPS60163823A (en) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd Oral administration pharmaceutical
EP0188040B1 (en) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Similar Documents

Publication Publication Date Title
RU97112089A (en) SOLID PHARMACEUTICAL COMPOSITION WITH REGULATED MEDICINAL RELEASE
RO117501B1 (en) Controlled-release pharmaceutical composition
HUT61989A (en) Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient
DE69629797D1 (en) MATRIX FOR CONTROLLED RELEASE OF MEDICINAL PRODUCTS
UA41446C2 (en) Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
RO116342B1 (en) Oral liquid pharmaceutical composition
IE831799L (en) Controlled release naproxen and naproxen sodium tablets.
YU66799A (en) An itraconazole exhibiting and improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same
CA2221356A1 (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
CA2253980A1 (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
RU96116411A (en) QUICKLY DISPERSABLE READY-FORMED DRUG FORM TRAMADOL OR TRAMADOL SALT
EP1035838A4 (en) Pharmaceutical suspension tablet compositions
WO2002017885A3 (en) Controlled release formulation of erythromycin or a derivative thereof
SI20108B (en) A controlled release formulation for poorly soluble basic drugs
DE60022230D1 (en) PROCESS FOR THE PREPARATION OF CLARITHROMYCIN POLYMORPHEN AND POLYMORPH IV
CA2234426A1 (en) Antibacterial composition for oral administration
CA2157323A1 (en) Gepirone dosage form
US3865935A (en) Tableting of erythromycin base
CA2423783A1 (en) Inhibition of systemic infections in humans and vertebrates by dietary fibers
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
RU2001128233A (en) A method of manufacturing pharmaceutical dosage forms and their precursors and pharmaceutical dosage form
RU2000119753A (en) SYNTHETIC POLYSACCHARIDES, METHOD FOR PRODUCING THERE AND THEIR PHARMACEUTICAL COMPOSITIONS
CA2240281A1 (en) Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases
WO2002042315A3 (en) Macrolide solvates
RU2000119750A (en) NEW PENTACCHARIDES, METHODS OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS